Treatment with Neuronal-Induced Human Mesenchymal Stem Cells Improves Functional Recovery of Acute Spinal Cord Injury through Attenuating Astrogliosis and Neurotoxic Astrocyte Activation.
Lee S., Hwang J., Jeong HS., Kim CH., Kim C., Jang S.
Animal Study on Spinal Cord Injury, published in J Korean Neurosurg Soc (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Korean Neurosurg Soc (2026)
- Country
- Korea (South)
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41679760
- DOI
- 10.3340/jkns.2025.0240
Abstract (original English)
Most of the preclinical studies have been focusing on inhibition of astrogliosis which is known as a major mechanism that inhibits recovery from spinal cord injury (SCI). Although mesenchymal stem cells (MSCs) have been widely studied as therapeutic candidates for SCI treatment, the role of MSCs on astrogliosis remains unclear. Furthermore, recent studies revealed that astrogliosis also has a protective role in SCI. The purpose of this study was to determine whether neural-induced human adipose tissue-derived MSCs (NI-hADSCs) promote SCI repair through astrogliosis modulation. NI-hADSCs were transplanted into the perilesional spinal cord in an acute severe SCI rat model. Functional recovery was evaluated serially on postoperative day 1 and weekly thereafter for 6 weeks using the Basso-Beattie-Bresnahan (BBB) locomotor rating scale. Western blot analysis was performed to assess protein levels of gliosis markers and neuroinflammatory pathways at 6 weeks post-injury. Histopathological examination was conducted at 6 weeks post-injury to evaluate astrogliosis and astrocyte phenotypic changes. NI-hADSC transplantation significantly improved functional recovery compared with the SCI group, as demonstrated by a greater cumulative BBB locomotor score over 6 weeks (AUC: 23.65 vs. 13.58, p = 0.026). At 6 weeks post-injury, the levels of glial fibrillary acidic protein (0.52 ± 0.11 vs. 1.0
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level AMeta-analysisPubMed
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Meta-analysis on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol - Level ASystematic ReviewPubMed
Brain-derived neurotrophic factor (BDNF) as biomarker in stem cell-based therapies of preclinical spinal cord injury models: A systematic review.
Systematic Review on Spinal Cord Injury, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
- 2025
Tissue Cell3 citations - Level ASystematic ReviewEurope PMC
Revolutionizing neural regeneration with smart responsive materials: Current insights and future prospects
Systematic Review on Spinal Cord Injury, published in Bioact Mater (2025) — summary generated from the PubMed abstract.
- 2025
Bioact Mater5 citations - Level ASystematic ReviewEurope PMC
Conductive Nanocomposite Hydrogels for Neural Tissue Engineering: A Systematic Scoping Review of Recent Trends
Systematic Review with a reported sample of 42 on Diabetic Foot, Stroke Research, Spinal Cord Injury, Neuroinflammation, published in Adv Sci (Weinh) (2025) — summary generated from the PubMed abstract.
- 2025
- n = 42
Adv Sci (Weinh)18 citations - Level ASystematic ReviewEurope PMC
Emerging regenerative strategies for spinal cord injury: exosome-derived mechanisms and therapeutic insights
Systematic Review on Spinal Cord Injury, Neuroinflammation, published in Front Neurosci (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurosci